Open AccessTempol treatment shows phenotype improvement in mdx mice
Author(s) -
Túlio de Almeida Hermes,
Rafael Dias Mâncio,
Aline Barbosa Macedo,
Daniela Sayuri Mizobuti,
Guilherme Luiz da Rocha,
Valéria Helena Alves Cag,
Elaine Minatel
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0215590
Subject(s) - duchenne muscular dystrophy , medicine , mdx mouse , saline , prednisolone , biceps , angiogenesis , phenotype , pharmacology , inflammation , endocrinology , pathology , dystrophin , chemistry , surgery , biochemistry , gene
Considering potential Tempol effects on mdx muscle fibers, in this study we evaluated its effects on relevant dystrophic phenotypic characteristics, such as muscle degeneration, inflammatory process and angiogenesis, which as yet have not been investigated. Mdx mice were randomly assigned into three groups: mdxS , the control group receiving intraperitoneal (i.p.) injections of saline solution (100μL); mdxP , positive control group receiving prednisolone (1mg/kg) by oral gavage; and mdx T, treated group receiving i.p. injections of tempol (100 mg/kg). C57BL/10 mice were also used as controls. Tempol treatment promoted gain in muscle strength and reduced myonecrosis and inflammatory response in the dystrophic diaphragm (DIA) and biceps brachii (BB) muscles. No evidence of Tempol's beneficial performance on angiogenesis in DIA and BB mdx muscles was found. The findings presented here show that Tempol treatment improves dystrophic phenotype, supporting its use as a potential therapeutic strategy in DMD.